1. Urothelial carcinoma (UC) and prostate cancer (PC) are the most common malignancy of the urinary system. The incidence is rising gradually due to the growing number of elderly people. The upper tract UC (UTUC) arising from renal pelvis and ureter accounts for only 5~10% of all UCs; however, the incidence of UTUC markedly increases to 40% of the UCs in Taiwan.

2. Assist pharmaceutical company to conduct clinical trial of new drug.

3. Conduct PI-initiated clinical trial.

4. Participate in international multi-center institution clinical trial.

5. Through TCTCGU, propose clinical trial to pharmaceutical company

6. Identify new biomarkers of UC and PC

7. Assist patients to find proper therapy strategy

Clinical trial

International cooperation

• Ramucirumab plus docetaxel versus placebo plus docetaxel in patients with locally advanced or metastatic urothelial carcinoma after platinum-based therapy (RANGE): overall survival and updated results of a randomised, double-blind, phase 3 trial
• Darolutamide in Nonmetastatic, Castration-Resistant Prostate Cancer
• Adjuvant Pembrolizumab after Nephrectomy in Renal-Cell Carcinoma
• Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer
• Durvalumab alone and durvalumab plus tremelimumab versus chemotherapy in previously untreated patients with unresectable, locally advanced or metastatic urothelial carcinoma (DANUBE): a randomised, open-label, multicentre, phase 3 trial
• Atezolizumab with or without chemotherapy in metastatic urothelial cancer (IMvigor130): a multicentre, randomised, placebo-controlled phase 3 trial
• Durvalumab Plus Olaparib in Previously Untreated, Platinum-Ineligible Patients With Metastatic Urothelial Carcinoma: A Multicenter, Randomized, Phase II Trial (BAYOU).
• FORT-1: Phase II/III Study of Rogaratinib Versus Chemotherapy in Patients With Locally Advanced or Metastatic Urothelial Carcinoma Selected Based on FGFR1/3 mRNA Expression.
• All drugs have been approved by FDA/TFDA.

Society aspect

• Combined biotechnology research of our consortium and other company research center
• Give suggestion of our clinical application view to company
• Offer clinical trial service before marketing
• Assist to evaluate new drug and medical device safety, efficacy
• To promote potential new drug and medical device marketing to benefit people